GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phio Pharmaceuticals Corp (NAS:PHIO) » Definitions » Shiller PE Ratio

Phio Pharmaceuticals (Phio Pharmaceuticals) Shiller PE Ratio : (As of May. 22, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Phio Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Phio Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Phio Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phio Pharmaceuticals Shiller PE Ratio Chart

Phio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Phio Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Phio Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Phio Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phio Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Phio Pharmaceuticals's Shiller PE Ratio falls into.



Phio Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Phio Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Phio Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.47/131.7762*131.7762
=-0.470

Current CPI (Mar. 2024) = 131.7762.

Phio Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -14,306.700 100.560 -18,747.931
201409 -9,081.250 100.428 -11,915.950
201412 -8,306.310 99.070 -11,048.524
201503 -6,617.340 99.621 -8,753.245
201506 -2,225.610 100.684 -2,912.903
201509 -2,536.590 100.392 -3,329.587
201512 -2,642.420 99.792 -3,489.325
201603 -2,253.540 100.470 -2,955.726
201606 -2,234.340 101.688 -2,895.450
201609 -2,214.210 101.861 -2,864.494
201612 -3,959.960 101.863 -5,122.861
201703 -1,748.980 102.862 -2,240.609
201706 -739.193 103.349 -942.515
201709 -692.993 104.136 -876.933
201712 -554.394 104.011 -702.386
201803 -593.994 105.290 -743.420
201806 -303.597 106.317 -376.299
201809 -224.398 106.507 -277.638
201812 -65.999 105.998 -82.050
201903 -68.520 107.251 -84.189
201906 -55.440 108.070 -67.602
201909 -54.360 108.329 -66.126
201912 -56.336 108.420 -68.472
202003 -15.960 108.902 -19.312
202006 -4.080 108.767 -4.943
202009 -4.800 109.815 -5.760
202012 -4.920 109.897 -5.900
202103 -3.840 111.754 -4.528
202106 -2.400 114.631 -2.759
202109 -3.360 115.734 -3.826
202112 -3.065 117.630 -3.434
202203 -2.340 121.301 -2.542
202206 -2.220 125.017 -2.340
202209 -3.140 125.227 -3.304
202212 -2.400 125.222 -2.526
202303 -3.150 127.348 -3.260
202306 -1.470 128.729 -1.505
202309 -1.140 129.860 -1.157
202312 -0.170 129.419 -0.173
202403 -0.470 131.776 -0.470

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Phio Pharmaceuticals  (NAS:PHIO) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Phio Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Phio Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Phio Pharmaceuticals (Phio Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
257 Simarano Drive, Suite 101, Marlborough, MA, USA, 01752
Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others.
Executives
Robert J Bitterman director C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Robert L Ferrara director 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Patricia A Bradford director UNISYS CORPORATION, 801 LAKEVIEW DRIVE, SUITE 100, BLUE BELL PA 19422
Gerrit Dispersyn officer: Chief Development Officer 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
John A Barrett officer: Chief Development Officer 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Geert Cauwenbergh director, officer: President and CEO 1 STULTS DRIVE, PLAINSBORO NJ 08536
Alexey Eliseev officer: Chief Business Officer 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Jonathan E Freeman director 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752
Curtis Lockshin director 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
H. Paul Dorman director 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581
Opko Health, Inc. 10 percent owner 4400 BISCAYNE BLVD., MIAMI FL 33137
Advanced Rna Technologies, Llc 10 percent owner 1 KENDALL SQUARE BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Keith L Brownlie director 777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Pamela Pavco officer: Chief Development Officer C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, WESTBOROUGH MA 01581
Caitlin Kontulis officer: Secretary and Controller 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581

Phio Pharmaceuticals (Phio Pharmaceuticals) Headlines

From GuruFocus